Imisopasem Manganese is a manganese-based non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and radioprotective activities. Metaphore Pharmaceuticals Inc. is developing Imisopasem Manganese for the potential treatment of pain, dermatological disease and inflammation. Upon administration, imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues.

Luxabendazole is a benzimidazole carbamate antihelmintic agent. In animal studies, it was effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes.

Enloplatin (CL 287110) is a platinum complex with antineoplastic properties. It is more water soluble than cisplatin. Enloplatin was developing by Wyeth-Lederle for the treatment of patients with ovarian cancer and leukemia.

Fenamifuril is an antiinflammatory and antirheumatic agent.

Naproxol is an aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic and an antipyretic.

Girisopam (GYKI 51189), a 2,3-benzodiazepine, is a compound with anxiolytic and antipsychotic action. It has shown these effects in several animal models. Girisopam differs from the traditional 1,4-benzodiazepines because of its selective anxiolytic action without muscle relaxant and anticonvulsive activity, and because it does not have affinity for 1,4-benzodiazepine receptors. Antidepressant activity of girisopam was also reported. The binding site of girisopam in neuronal cells in the central nervous system is located exclusively to the basal ganglia. Because the danger of tolerance and dependence is lower for 2,3-benzodiazepine than 1,4-benzodiazepines, girisopam may potentially be used in treatment of addiction and affective disorders. No clinical trials were conducted in the US.

Rilmakalim (HOE-234) is a potassium channel activator and dilator of bronchial and vascular smooth muscles. An animal study showed that rilmakalim is effective against contractile response induced by asthma mediators in guinea pig airways and has the potential to act against asthma attacks, because it acts on acute bronchospasm. The activation of ATP-sensitive potassium channels is likely to be involved in the smooth muscle relaxation produced by rilmakalim in human airways. This drug has been investigated for use in asthma and coronary disorders, but development has been discontinued.

Naluzotan (PRX-00023), a small molecule, non-azapirone, dual serotonin (5-HT)1A receptor agonist and sigma-1 receptor antagonist, is under development with Proximagen for the treatment of epilepsy. In previous clinical trials, the compound was shown to be safe and well-tolerated in over 400 patients. Epilepsy patients with localisation-related epilepsy have reduced 5-HT1a receptor binding as indicated by positron emission tomography (PET scan). It is thought that by increasing neurotransmitter activity at 5-HT1a receptor sites, seizure incidence and severity may be decreased.